DENTAL MANAGEMENT OF PATIENTS ON ANTIPLATELET THERAPY: LITERATURE UPDATE by Kumar MP, Santhosh
Vol 9, Issue 3, 2016
Online - 2455-3891 
Print - 0974-2441
DENTAL MANAGEMENT OF PATIENTS ON ANTIPLATELET THERAPY: LITERATURE UPDATE
SANTHOSH KUMAR MP*
Department of Oral and Maxillofacial Surgery, Saveetha Dental College, Velappanchavadi, Chennai - 600 077, Tamil Nadu, India. 
Email: santhoshsurgeon@gmail.com
Received: 03 March 2016, Revised and Accepted: 13 March 2016
ABSTRACT
Antiplatelet drugs are used in the prevention and management of arterial and venous thrombi. These drugs are associated with an increase in bleeding 
time and risk of post-operative hemorrhage. Because of this, dental surgeons recommend their patients to stop the therapy before surgical procedures 
which may in turn cause fatal thromboembolic complications. This article reviews the commonly used antiplatelet drugs, dental management of 
patients on these drugs when subjected to minor oral surgical procedures. The objective of this article is to review various literature, whether to 
discontinue or continue antiplatelet therapy during dental surgical procedures, and current consensus and recommendations have been established. 
It is concluded that antiplatelet monotherapy and even antiplatelet dual therapy can be safely continued on patients during dental surgical procedures, 
and there is no need for altering or discontinuing the drugs. Post-operative bleeding can be managed by local hemostatic measures.
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INTRODUCTION
Thrombogenesis (clot formation) includes 2 principal processes: platelet 
aggregation and coagulation. Platelet aggregation consists of activated 
platelets attaching to strands of fibrinogen, whereas coagulation is 
a complex cascade of enzymatic events, leading to the formation of 
fibrin strands. Antithrombotic drugs include those that inhibit platelet 
aggregation (antiplatelet drugs), inhibit formation of fibrin strands 
(anticoagulants), and dissolve existing clots (fibrinolytics) [1].
Platelets provide the initial hemostatic plug at the site of vascular injury, 
and they are involved in pathological processes and are an important 
contributor to arterial thrombosis, leading to myocardial infarction 
and ischemic stroke. Antiplatelet agents are widely used in prevention 
and treatment of various ischemic cardiovascular and cerebrovascular 
conditions [2], and the common indications for their long-term use are 
arterial thrombosis, ischemic heart disease, myocardial infarction, both 
stable and unstable angina, coronary artery bypass and placement of 
a stent, non-hemorrhagic stroke, transient ischemic attacks (ischemic 
stroke), peripheral arterial disease, atrial fibrillation.
Despite the benefits of antiplatelet drugs, they are not without the 
risks of bleeding during oral surgical procedures. Hence, dentists while 
treating patients on antiplatelet therapy advise them to stop drugs 
before extractions which may predispose them to thromboembolic 
complications. Hence, dental surgeons are in a dilemma whether to 
stop or continue antiplatelet drugs during extractions. Various studies 
have been conducted worldwide to address this issue. The rationale 
of this article is to review the present literature on this topic and to 
obtain the updated and recent consensus and recommendations made 
while treating patients on antiplatelet therapy undergoing oral surgical 
procedures.
ANTIPLATELET DRUGS
Drug Mechanism of action
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COX: Cyclooxygenase, ADP: Adenosine diphosphate
Mechanism of action – antiplatelet drugs
ASPIRIN
Aspirin, acetylsalicylic acid (ASA), is a non-steroidal anti-inflammatory 
drug that exhibits analgesic, antipyretic, anti-inflammatory, and 
antiplatelet properties. It is the most commonly used drug in the 
prevention and treatment of thromboembolic diseases because of its 
antiplatelet action. Aspirin has been shown to be a powerful secondary 
prevention agent, reducing the risk of myocardial infarction and 
ischemic stroke by up to 20% in patients diagnosed with cardiovascular 
disease [3]. Its mechanism of action involves an irreversible inhibition 
of the activity of cyclooxygenase-1 (COX-1) and a modification of 
the enzymatic activity of COX-2. COX is an enzyme responsible for 
the conversion of arachidonic acid to prostaglandins, prostacyclin, 
and thromboxane. Thromboxane-A2, a strong platelet agonist, is a 
specific eicosanoid lipid found in platelets important in promoting 
platelet aggregation over-damaged endothelium in blood vessels. 
The irreversible nature of the inhibition of COX is unique to aspirin 
among its counterparts [3,4]. Platelets are affected for the life of the 
cell, and complete reversal of antiplatelet activity might not occur until 
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approximately 2 weeks after cessation of therapy. The best screening 
test to evaluate the effect of aspirin on platelets is the platelet function 
analyzer-100 which is equally effective and less invasive than the Ivy 
bleeding time. The prothrombin time, activated partial thromboplastin 
time, and platelet count are usually normal in patients on aspirin 
therapy, but the bleeding time may be prolonged. Dosage: 75-150 mg 
for long-term prevention of thrombo-embolic events and 300 mg as a 
loading dose for acute clinical conditions (acute myocardial infarction, 
stroke, unstable angina) was used.
CLOPIDOGREL
Clopidogrel is an antiplatelet drug with a mechanism of action causing 
irreversible inhibition of an adenosine diphosphate receptor important 
in promoting platelet aggregation and cross-linking of platelets by 
fibrin. It is first activated in the liver by cytochrome P450 enzymes [5]. 
Clopidogrel is very expensive and is used in patients who are resistant 
to aspirin. Action starts within 2 hrs of ingestion, and antiplatelet 
effect lasts for lifetime of the platelets. At present, in dual antiplatelet 
therapy, clopidogrel is most commonly used with aspirin to prevent 
thromboembolic events in high-risk patients. It is an alternative drug 
for persons who require anticoagulation and who are unable to tolerate 
aspirin therapy. The dosage used is 75-100 mg/day, with a half-life of 
8 hrs.
TICLOPIDINE
Ticlopidine also functions as an adenosine diphosphate receptor 
inhibitor. It is used to treat patients who cannot tolerate aspirin or for 
whom dual antiplatelet therapy is desirable. Because ticlopidine has 
been reported to increase the risk of thrombotic thrombocytopenic 
purpura and neutropenia, it has largely been replaced by clopidogrel 
which is believed to confer a much lower hematologic risk [6].
DIPYRIDAMOLE
Dipyridamole is a drug that exhibits both antiplatelet and vasodilatory 
activities. In patients with ischemic cardiomyopathy, it has been shown 
to increase both myocardial perfusion and left ventricular function 
and to decrease pulmonary hypertension, used as an adjunct to oral 
anticoagulation for the prophylaxis of thromboembolism associated 
with prosthetic heart valves. Its mechanism of action involves the 
inhibition of the enzyme thromboxane synthase, resulting in lower 
levels of thromboxane-A2 and decreased platelet aggregation, similar 
to aspirin. Dipyridamole also impairs platelet aggregation by causing 
an elevation in the serum levels of cyclic adenosine monophosphate 
through inhibition of the phosphodiesterase enzymes that break it 
down [7,8]. Dipyridamole produces vasodilation through its inhibition 
of the cellular reuptake of adenosine into platelets, red blood cells, and 
endothelial cells. This results in increase of extracellular adenosine 
which promotes vasodilation. Its presence also results in reductions 
in the number of thrombin and platelet endothelial cell adhesion 
molecule-1 receptors on platelets in patients with stroke. Despite all 
this activity, dipyridamole has been shown to be less effective than 
aspirin as an adenosine diphosphate receptor inhibitor, and its action 
on phosphodiesterase is fully reversed 24 hrs after discontinuation of 
the drug. Therefore, it has been less commonly prescribed than other 
antiplatelet medications [7,8].
COMBINATION THERAPY
Low doses of aspirin, clopidogrel, ticlopidine, and dipyridamole are the 
most common antiplatelet drugs, and they inhibit platelet function by 
different mechanisms. Aspirin, clopidogrel, ticlopidine, and prasugrel 
(thienopyridines) affect the activity of platelets during their lifetime 
(7-10 days). These drugs are given individually as monotherapy or 
sometimes combined, two drugs as dual therapy because they work 
in different ways and have synergistic effect [9]. The combination of 
low-dose aspirin (150 mg) and clopidogrel (75 mg) is mainly used to 
prevent thrombotic complications after percutaneous insertion of a 
coronary stent [8]. This combination is used for 4-12 weeks following 
the insertion of a bare metal stent and for 6-12 months following 
the insertion of a drug-eluting stent [10]. Sometimes, antiplatelet 
drugs are combined with anticoagulant drug to achieve the desired 
anticoagulant activity in high-risk patients. The combination of aspirin 
plus dipyridamole is used for the prevention of strokes or transient 
ischemic attacks.
ANTIPLATELET THERAPY AND ORAL SURGERY
Despite the benefits of antiplatelet drugs, they are not without risk in 
that they can increase the risk of bleeding, particularly gastrointestinal 
bleeding, hemorrhagic stroke, and post-operative bleeding. In patients 
who take combinations of antiplatelet drugs, the risk is higher because 
of their synergistic effect. Although many surgical procedures are done 
in oral cavity, exodontia is the simplest and commonest procedure 
done in dentistry. When dental surgeons treat patients on antiplatelet 
therapy, they are in a dilemma whether or not to suspend aspirin before 
extraction. Dentists typically advise patients to stop taking aspirin 
before tooth extraction for fear of excess bleeding. The effect of aspirin 
starts within 1 hr of ingestion and lasts for 7-10 days, i.e., lifespan of 
a platelet [10]. Therefore, traditionally, it was recommended to stop 
aspirin therapy 7-10 days before invasive surgical procedure and 
was restarted 24-48 hrs after surgery. The idea is to allow 10 days 
time for regeneration of newer platelets as the platelets replenish 
approximately at the rate of 10% a day. However, this can result in 
thromboembolic events (e.g., deep-vein thrombosis and pulmonary 
embolism) within 10 days of stopping the drugs that are worse for the 
patient than post-operative bleeding. One has to maintain the balance 
between risk of increased bleeding and risk of thromboembolic events. 
On theoretical basis, stopping aspirin decreases the risk of bleeding but 
increases risk of thromboembolic events, whereas continuing aspirin 
decreases risk of thromboembolic events but increases risk of bleeding.
Various studies were conducted to determine whether to continue or 
discontinue antiplatelet medications during dental surgical procedures, 
and the literature review is presented here to arrive at a conclusion.
Studies recommending discontinuation of antiplatelet therapy
Lemkin et al. [11] in 1974 explained bleeding after oral surgery with 
aspirin therapy which required platelet transfusion for correction. 
McGaul [12] and Daniel et al. [13] stated that continuing aspirin caused 
post-operative bleeding and advised discontinuation for 7-10 days 
before surgical procedures. This was recommended on the basis of 
surgical studies which showed rise in both intra- and post-operative 
bleedings. Some authors advised that stopping of antiplatelets only 
for 3 days will be sufficient. Studies by Conti [14], Speechley and 
Rugman [15], Scher [16], Scully and Wolf [17], Little et al. [18], and 
Burger et al. [19] recommended stoppage of antiplatelets to avoid the 
risks of post-operative bleeding.
Thomason et al. [20] in their study found bleeding after gingival 
surgery with aspirin therapy and advised to discontinue aspirin before 
surgery. Elad et al. [21] reported a case of severe bleeding episode, 
following nonsurgical periodontal treatment in a patient taking dual 
antiplatelet therapy (aspirin 100 mg plus clopidogrel 75 mg/day). 
Severe life-threatening hemorrhage occurred post-operatively leading 
to hemorrhagic shock. Schrodi et al. [22] found increased bleeding on 
probing in patients who consumed aspirin in a dose of 325 mg/day 
for 7 days. A case was reported by Foulke in which bleeding episode 
occurred after oral prophylaxis with ultrasonic scaler [23]. Several 
studies have documented the risk of bleeding in patients on antiplatelet 
therapy undergoing cardiac surgeries [24-26].
Risks of withdrawal of antiplatelet therapy
However, scientific evidence showed that stopping antiplatelet therapy 
is associated with a progressive recovery of platelet function and 
with a potential risk of rebound of thromboembolic vascular events 
due to excessive thromboxane-A2 activity and decreased fibrinolytic 
activity [27,28]. Ferrari et al. [29] and Chassot et al. [30] suspected the 
existence of a biological platelet rebound phenomenon on interruption 
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of aspirin therapy, thus creating a prothrombotic state which may 
ultimately cause fatal thromboembolic events. Other studies showed 
potential risk of fatal thromboembolic events such as myocardial 
infarction and stroke on stopping aspirin therapy [31-35]. One study 
pointed out that suspending aspirin therapy resulted in a 3-fold increase 
in the incidence of cerebral infarction and major cardiovascular events 
compared with continuation of the therapy [36]. Discontinuation of 
antiplatelet therapy in high-risk patients has been shown to increase 
the risk of cardiac complications and death. Wahl and Howell [37] 
were one of the first groups of authors to conclude that the risk of 
hemorrhage after dental surgery may be greatly outweighed by the risk 
of thromboembolism after withdrawal of anti-thrombotic therapy.
A systemic review and meta-analysis on the potential risks and health 
hazards of stopping aspirin by Biondi-Zoccai et al. confirmed the major 
detrimental impact of withdrawal across a greater number of individuals 
(50,279) at risk for coronary artery disease [38]. Ferrari et al. [29] in 
his study have evaluated the role of aspirin withdrawal in a cohort of 
1236 patients hospitalized for acute coronary syndrome. A total of 
51 (4.1%) of these patients discontinued aspirin within 1 month of the 
acute coronary syndrome. Thirteen of these acute coronary syndrome 
cases were withdrawn from aspirin before a dental procedure. The 
mean delay between aspirin withdrawal and acute coronary event was 
between 4 and 17 days, and the risk of thromboembolic events increases 
between 4 and 30 days of withdrawal of antiplatelet therapy [29]. 
Collet et al. performed retrospective analysis of 475 patients admitted 
to the hospital with the diagnosis of myocardial infarction. Eleven 
patients stopped aspirin therapy within 15 days before general surgical 
procedure. Another nine patients stopped aspirin 3 days before elective 
surgical procedures, one of which was a dental surgical procedure. 
This dental patient was stable and asymptomatic for 10 years with 
continued use of aspirin. Unfortunately, myocardial infarction occurred 
10 days after stopping aspirin therapy [39,40].
Studies recommending continuation of antiplatelet therapy
Bajkin et al. [41] in their study concluded that patients taking single 
or dual antiplatelet drugs may have teeth extracted safely without 
interruption of treatment using only local hemostatic measures to 
control post-operative bleeding. Verma et al. [42] in their prospective 
study concluded that there is no need to stop the antiplatelet dose of 
aspirin prior to simple tooth extraction as there was 0% incidence of 
post-operative bleeding in their patients. Olmos-Carrasco et al. [43], 
in their prospective study on 181 patients who underwent dental 
extractions observed regarding hemorrhagic complications, concluded 
the safety of dental extraction without withdrawal of double antiplatelet 
therapy. The American College of Chest Physicians recommends 
continuing the antiplatelet drugs perioperatively in patients who 
require operation within 6 weeks of placement of a metal stent or 
6 months of placement of a drug-eluting stent. Acute myocardial 
infarction has followed in such patients after withdrawal of antiplatelet 
therapy [44,45].
Girotra et al. [46] from their prospective study concluded that there 
was no necessity to stop antiplatelet therapy, and higher levels of 
bleeding measures are necessary in patients with dual antiplatelet 
therapy. According to a study by Hanken et al. [47], continued aspirin 
therapy in patients undergoing dental osteotomies has no effect on the 
incidence of post-operative bleeding and should not be interrupted. 
Nooh [48] in his study concluded that subjects who received 81 mg 
ASA daily could undergo dental extraction without bleeding risks. van 
Diermen et al. [49] in their literature review suggest not to interrupt 
oral antithrombotic medication, not even dual antiplatelet therapy, in 
simple dental procedures. Broekema et al. [50] from their prospective 
study concluded that dentoalveolar surgery is safe in patients being 
treated with anticoagulants.
Many other studies have recommended that dental extractions 
can be carried out safely without discontinuation of antiplatelet 
therapy [51-59]. Studies related to general and cardiovascular surgery 
also did not show any significance increase in bleeding in patients on 
antiplatelet drugs [60,61]. Zhao et al. [62] from their meta-analysis 
stated that they could not conclude that bleeding time or the extent 
of hemorrhage in dental extraction is prolonged when patients are on 
long-term aspirin therapy and recommend not to stop antiplatelet drugs 
before tooth extraction and that the hemostasis method is enhanced. 
Napenas et al. [63] conducted a retrospective analysis to evaluate the 
risk of bleeding complications in patients on single or dual antiplatelet 
therapy, undergoing invasive oral surgical procedures including 
dental extractions. They concluded that risk of stopping antiplatelet 
therapy and predisposing the patient to thromboembolic events far 
overweighed the negligible risk of bleeding from dental procedures.
Krishnan et al. concluded that patient continuing aspirin therapy can 
undergo routine dental extractions without increased risk of excessive 
or prolonged bleeding [56]. Bajkin et al. conducted a prospective 
study to evaluate the post-extraction bleeding in patients on aspirin 
monotherapy, oral anticoagulant therapy, and dual therapy with 
aspirin + oral anticoagulant (71 patients in each group). None of the 
patients on aspirin monotherapy had post-operative bleeding [51]. 
Lillis et al. performed a prospective study to compare the incidence of 
bleeding complications among patients taking aspirin monotherapy, 
clopidogrel monotherapy, and dual therapy with both aspirin and 
clopidogrel and patients not taking aspirin at all. The results showed 
that greater number of patients on dual antiplatelet therapy showed 
prolonged immediate bleeding when compared to control healthy 
patient group, and the difference was statistically significant. Although 
there is greater incidence of prolonged immediate bleeding in dual 
antiplatelet therapy group, hemostasis is achieved easily by local 
hemostatic measures. Therefore, they concluded that the patient 
should not be predisposed to risk of thromboembolism by stopping 
either antiplatelet monotherapy or dual therapy [64]. Madan et al. 
concluded that most minor oral surgical procedures can be carried out 
safely without interrupting long-term low-dose aspirin therapy [58].
According to Scully and Wolf for uncomplicated forceps extraction of 
1 to 3 teeth, there is no need to interfere the aspirin dose. In patients 
taking 100 mg of aspirin a day, bleeding can be controlled by suturing 
and local hemostatic measures. In patients taking higher dose of 
aspirin, if the current value of bleeding time is more than 20 minutes, 
then surgical treatment should be postponed [17]. Little et al. [18], 
Gaspar et al. [65], and Sonksen et al. [66] claimed that there are no 
significant intra- and post-operative bleedings after dental extractions 
as long as prolongation in bleeding time remains within acceptable limit 
(bleeding time up to 20 minutes) preoperatively. The study of Blinder 
et al. [67] concluded that dental extraction could be performed without 
interruption in patients’ treatment with oral anticoagulants. Another 
recent study stated that there was no need to discontinue either the 
anticoagulant or aspirin in the patients taking the combined oral 
anticoagulant-aspirin regimen who required dental extraction [51].
Napeñas et al. [53] and Morimoto et al. [52] from their studies suggest 
that the risk for post-operative bleeding complications is greater with 
warfarin, either alone or in combination with antiplatelet medications, 
than antiplatelet medications alone. The results of their review 
suggest that there is no indication to alter or discontinue antiplatelet 
therapy before invasive dental procedures and post-operative bleeding 
can be managed by local hemostatic measures. Ardekian et al. [68] 
concluded that dental extractions can be performed in patients on 
continued antiplatelet therapy. A recent survey of vascular surgeons 
showed that most did not stop the administration of antiplatelet 
drugs pre-operatively [69]. One might assume that the risk of bleeding 
complications would be much greater with vascular procedures 
(i.e., carotid endarterectomy or infrainguinal bypass) than with routine 
exodontia.
In a study by Cañigral et al. [70], 4 of the 9 patients (44.4%) receiving 
dual therapy had moderate hemorrhage that was defined as hemorrhage 
lasting more than 10 minutes and was stopped using local hemostatic 
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measures in less than 60 minutes in all cases. A study by Park et al. [71] 
with all dental extractions included 100 patients with double and triple 
antiplatelet therapy; only 2 cases of excessive hemorrhage (lasting 4 and 
5 hrs) were found. According to Bassand et al., dual antiplatelet therapy 
was found to increase major bleeding events by 1% as compared to 
aspirin monotherapy, but no life-threatening complications were 
reported and no transfusions were required [72]. Morimoto et al. in 
their study reported post-operative bleeding of 1.4% for single or dual 
antiplatelet therapy, 4.1% for warfarin, and 8.2% for combined warfarin 
and antiplatelet therapy after teeth extractions [52]. The same group 
performed a similar study involving periodontal therapy (e.g. scaling 
and root planing, periodontal surgery), with post-operative bleeding 
occurrences of 0%, 1.4%, and 3.4% for antiplatelet therapy, warfarin, 
and combined warfarin and antiplatelet therapy, respectively [73] 
but were managed by local hemostatic measures. Duygu et al. [74], 
and Medeiros et al. [75] have assessed the bleeding risk in patients 
on antiplatelet therapy during dental invasive procedures and have 
concluded to be safe to continue the drugs.
ORAL SURGERY CONSIDERATIONS
Minor surgical procedures such as simple extraction of up to three 
teeth, gingival surgery, crown and bridge procedures, supragingival 
scaling, and surgical removal of teeth can be safely carried out without 
altering the antiplatelet medication dose. If more than three teeth need 
to be extracted, then multiple visits will be required and the extractions 
may be planned to remove 2-3 teeth at a time, by quadrant, or one at a 
time in separate visits. Scaling and gingival surgery should initially be 
restricted to a limited area to assess if bleeding is problematic.
MANAGEMENT OF POST-OPERATIVE BLEEDING
Post-operative bleeding has more serious consequences for surgeries of 
the abdomen or thoracic cavity, which have compartment spaces where, 
after wound closure, post-operative bleeding is invisible. In contrast, 
the consequences of possible hemorrhage in non-compartment 
surgeries are greatly outweighed by the risk associated with cessation 
of antiplatelet therapy, which can result in acute coronary syndrome in 
serious cases [76,77]. Dental surgery is a non-compartment procedure, 
and bleeding in the oral cavity is immediately visible and can therefore 
be treated without delay [78].
All patients receiving antiplatelet medications must be considered to 
have drug-induced altered platelet function. There will be an increased 
bleeding tendency if two antiplatelet agents are used in combination 
than with monotherapy. Several studies were conducted to assess 
the risk of post-operative bleeding in patients on antiplatelet drugs 
undergoing dental surgical procedures, and it was found to be safe 
to continue the drugs during dental treatment [74,75]. Morimoto 
et al. [52], Scully and Wolff [17], and Lillis et al. [64] have reported 
acute inflammation in the form of gingivitis and periodontitis as 
the aggravating factor of hemorrhage post-extraction in patients 
on antithrombotic therapy. Other factors which increase the risk of 
post-operative bleeding are extraction time, surgical tooth extraction, 
and 3-root extractions [43]. Granulation tissue in extraction sockets 
should be removed before placement of hemostatic agents as it is a 
frequent source of post-extraction bleeding.
Aspirin can double the baseline bleeding time, but this may still be 
within or just outside the normal range. Clopidogrel is considered a 
more potent antiplatelet agent and can prolong the bleeding time by 
1.5-3 times normal. Sensitivity to antiplatelet agents varies from one 
person to another. According to Thomas et al. [79], Brennan et al. [55], 
and Ardekian et al. [68], cutaneous bleeding time as a screening 
procedure to predict post-operative oral bleeding cannot be accepted. 
The platelet aggregation test is said to be more acceptable test in 
assessing platelet function.
Patients taking antiplatelet medications will have prolonged bleeding 
time, but this may not be clinically relevant because post-operative 
bleeding after dental procedures can mostly be controlled using local 
hemostatic measures. Lockhart et al. [80] suggested post-operative 
bleeding as clinically significant if it fulfills any of the following four 
criteria:
1. Bleeding that continued >12 hrs of surgical procedure,
2. Bleeding that makes the patient report back for management,
3. Bleeding that results in large hematoma formation or ecchymosis,
4. Bleeding that required blood transfusion.
LOCAL HEMOSTATIC MEASURES
Surgeons most often apply pressure (biting firmly on gauze for 
30 minutes), use a hemostatic matrix such as oxidized regenerated 
cellulose, absorbable gelatin sponge, or collagen with figure of 
eight sutures applied to the extraction socket. The hemostatic 
properties of these agents are based on their ability to activate 
the coagulation cascade locally. They have no intrinsic coagulation 
factors or activities but are designed to stimulate clot formation by 
providing a 3-dimensional scaffold used for clot organization. Others 
include topical thrombin, bone wax (ostene), 4.8% tranexamic acid 
mouthwash [81,82], HemCon Dental Dressing (chitosan-based agent), 
hemostatic solutions (aluminum solution), tannic acid, and fibrin glue. 
Newer local hemostatic agents under consideration include zeolite 
(QuikClot), chitosan-based agents (N-acetyl glucosamine polymer), and 
poly-N-acetyl glucosamine agents. Patients are strictly advised to follow 
the post-operative instructions for the maintenance of the blood clot.
SUMMARY
Patients must be treated based on the following protocol:
1. Assessing status of their medical condition,




5. Close extended post-operative monitoring.
Dual antiplatelet therapy is given for high-risk patients, especially those 
with coronary stents. Hence, premature withdrawal of these drugs 
can result in myocardial infarction and death. The American Heart 
Association, American College of Cardiology, Society for Cardiovascular 
Angiography and Interventions, American College of Physicians, 
American College of Surgeons, American Dental Association, National 
Health Service, and numerous authors recommend either maintaining 
double antiplatelet therapy in dental interventions and applying the 
necessary local hemostatic measures to control the hemorrhage or 
delaying the intervention until the dual therapy can be withdrawn 
without risk [44,45].
A review of the literature showed the risk of bleeding under continued 
aspirin use to increase by 1.5-fold, but that this can be controlled with 
local hemostatic measures with no life-threatening bleeding. Dual 
antiplatelet therapy was found to increase major bleeding events 
by 1% as compared to aspirin monotherapy, but no life-threatening 
complications were reported and no transfusions were required 
and can be managed by local hemostatic measures. An increased 
rate of surgical bleeding has also been reported with the use of 
clopidogrel, but this was found not to influence patient morbidity and 
mortality. Hence, there is no need to expose the patient to the risk of 
thromboembolism, cerebrovascular accidents, or myocardial or renal 
infarction by discontinuing antiplatelet therapy before minor oral 
surgical procedures, which could cost the patient’s life [83].
CONCLUSION
1. Antiplatelet monotherapy or even antiplatelet dual therapy need not 
be altered or stopped before minor oral surgical procedures.
2. Most of the post-operative bleeding can be easily controlled by local 
hemostatic measures.
3. However, patients on combined anticoagulant and antiplatelet 
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therapy or dual antiplatelet therapy appear to be at increased risk 
for post-operative bleeding complications, when major oral surgical 
procedures are performed and their management warrants added 
consideration (higher levels of hemostatic measures and appropriate 
consultation with the physician are necessary).
4. The risk of hemorrhage after dental surgery may be greatly 
outweighed by the risk of thromboembolism after withdrawal of 
anti-thrombotic therapy.
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